Annual report pursuant to Section 13 and 15(d)

License and Technology Agreements

v3.10.0.1
License and Technology Agreements
12 Months Ended
Sep. 30, 2018
License and Technology Agreements [Abstract]  
License and Technology Agreements

NOTE 6 – LICENSE AND TECHNOLOGY AGREEMENTS

 

As a result of a Licensing Agreement between Avant Diagnostics, Inc. and George Mason University (“GMU”), Avant has the exclusive rights to commercialize 5 patents, associated with GMU’s RPPA technology, licensed from GMU. Also, Avant has the right of first refusal for all technology associated with RPPA technology from GMU.

 

The National Institute of Health (“NIH”) has also licensed 3 patents to Avant in the area of RPPA technology.

 

The Company’s intangible assets consist of technology enhancements and licensing payments for its worldwide exclusive licensed rights to OvaDx ®, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer.